Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1955 1
1956 2
1957 5
1958 2
1959 1
1962 1
1963 1
1964 2
1966 2
1967 1
1968 1
1969 2
1972 2
1978 2
1979 2
1980 1
1981 2
1983 2
1986 3
1989 1
1992 1
1994 1
1996 1
1998 1
1999 2
2000 3
2001 2
2002 2
2003 9
2004 5
2005 9
2006 8
2007 6
2008 8
2009 6
2010 6
2011 3
2012 5
2013 6
2014 11
2015 8
2016 6
2017 10
2018 8
2019 6
2020 15
2021 21
2022 19
2023 14
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Results by year

Filters applied: . Clear all
Page 1
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. Among authors: mcgowan bm. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. N Engl J Med. 2021. PMID: 33567185 Clinical Trial.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. Among authors: mcgowan bm. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. Diabetes Obes Metab. 2022. PMID: 35441470 Free PMC article. Clinical Trial.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Lincoff AM, et al. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 37952131 Clinical Trial.
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. O'Neil PM, et al. Among authors: mcgowan b. Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16. Lancet. 2018. PMID: 30122305 Clinical Trial.
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. Pi-Sunyer X, et al. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892. N Engl J Med. 2015. PMID: 26132939 Free article. Clinical Trial.
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. le Roux CW, et al. Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23. Lancet. 2017. PMID: 28237263 Clinical Trial.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. Lau DCW, et al. Among authors: mcgowan b. Lancet. 2021 Dec 11;398(10317):2160-2172. doi: 10.1016/S0140-6736(21)01751-7. Epub 2021 Nov 16. Lancet. 2021. PMID: 34798060 Clinical Trial.
Appetite control.
Wynne K, Stanley S, McGowan B, Bloom S. Wynne K, et al. Among authors: mcgowan b. J Endocrinol. 2005 Feb;184(2):291-318. doi: 10.1677/joe.1.05866. J Endocrinol. 2005. PMID: 15684339 Review.
The bariatric physician.
Grant P, Piya M, McGowan B, Taheri S. Grant P, et al. Among authors: mcgowan b. Clin Med (Lond). 2014 Feb;14(1):30-3. doi: 10.7861/clinmedicine.14-1-30. Clin Med (Lond). 2014. PMID: 24532740 Free PMC article.
EMJ COVID-19 monthly top five (June 2021).
Chatha R, Reed M, Jennings H, McClatchey A, Shahin A, Williamson C, McGowan B, Oliver G. Chatha R, et al. Among authors: mcgowan b. Emerg Med J. 2021 Aug;38(8):650-652. doi: 10.1136/emermed-2021-211796. Emerg Med J. 2021. PMID: 34449433 Review. No abstract available.
221 results